CN105451777A - 自身免疫性疾病的治疗 - Google Patents

自身免疫性疾病的治疗 Download PDF

Info

Publication number
CN105451777A
CN105451777A CN201480015896.9A CN201480015896A CN105451777A CN 105451777 A CN105451777 A CN 105451777A CN 201480015896 A CN201480015896 A CN 201480015896A CN 105451777 A CN105451777 A CN 105451777A
Authority
CN
China
Prior art keywords
polynucleotide
alopecia
coli
sequence
cpg dinucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480015896.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·P·埃舍尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Loma Linda University
Original Assignee
Loma Linda University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loma Linda University filed Critical Loma Linda University
Priority to CN201910567251.0A priority Critical patent/CN110237270A/zh
Publication of CN105451777A publication Critical patent/CN105451777A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
CN201480015896.9A 2013-03-15 2014-03-14 自身免疫性疾病的治疗 Pending CN105451777A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910567251.0A CN110237270A (zh) 2013-03-15 2014-03-14 自身免疫性疾病的治疗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361800354P 2013-03-15 2013-03-15
US61/800,354 2013-03-15
PCT/US2014/029685 WO2014145042A1 (en) 2013-03-15 2014-03-14 Treatment of autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910567251.0A Division CN110237270A (zh) 2013-03-15 2014-03-14 自身免疫性疾病的治疗

Publications (1)

Publication Number Publication Date
CN105451777A true CN105451777A (zh) 2016-03-30

Family

ID=51537869

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480015896.9A Pending CN105451777A (zh) 2013-03-15 2014-03-14 自身免疫性疾病的治疗
CN201910567251.0A Pending CN110237270A (zh) 2013-03-15 2014-03-14 自身免疫性疾病的治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910567251.0A Pending CN110237270A (zh) 2013-03-15 2014-03-14 自身免疫性疾病的治疗

Country Status (8)

Country Link
EP (1) EP2968606B1 (https=)
JP (3) JP6499155B2 (https=)
CN (2) CN105451777A (https=)
AU (2) AU2014233428B2 (https=)
CA (1) CA2902565C (https=)
DK (1) DK2968606T3 (https=)
ES (1) ES2825078T3 (https=)
WO (1) WO2014145042A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110237270A (zh) * 2013-03-15 2019-09-17 洛马林达大学 自身免疫性疾病的治疗

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2758074T3 (da) 2011-09-23 2020-07-27 Univ Loma Linda Bakteriestammer der udtrykker methylasegener og anvendelser deraf
US11680273B2 (en) 2011-09-23 2023-06-20 Loma Linda University Treatment of autoimmune diseases
WO2016135732A1 (en) * 2015-02-26 2016-09-01 Yeda Research And Development Co. Ltd. Method of promoting hair growth

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2058393B1 (en) * 2005-05-11 2010-07-07 Loma Linda University Compositions and methods for preventing and treating immune-mediated inflammatory disorders
WO2013044177A2 (en) * 2011-09-23 2013-03-28 Loma Linda University Bacterial strains expressing methylase genes and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
DE3223885A1 (de) 1982-06-26 1983-12-29 Basf Ag, 6700 Ludwigshafen Makroporoese, hydrophile traeger fuer enzyme
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4871488A (en) 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US5179022A (en) 1988-02-29 1993-01-12 E. I. Du Pont De Nemours & Co. Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6132419A (en) 1992-05-22 2000-10-17 Genetronics, Inc. Electroporetic gene and drug therapy
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
AU686277B2 (en) 1993-11-16 1998-02-05 Pacira Pharmaceuticals, Inc. Vesicles with controlled release of actives
US5549127A (en) 1995-05-03 1996-08-27 Chang; Wen-Hsiung Spring fixing structure for a hairgrip
US5763270A (en) 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
EP0914094A4 (en) 1996-03-28 2000-03-01 Univ Illinois MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS
US5851818A (en) 1996-05-31 1998-12-22 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6233483B1 (en) 1997-05-14 2001-05-15 Pacesetter, Inc. System and method for generating a high efficiency biphasic defibrillation waveform for use in an implantable cardioverter/defibrillator (ICD).
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6800484B2 (en) 1998-06-24 2004-10-05 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
AU2868200A (en) 1999-02-08 2000-08-25 Chiron Corporation Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
EP1890606A1 (en) * 2005-04-25 2008-02-27 Koninklijke Philips Electronics N.V. Method and apparatus for continuous imaging by ultrasound transducer system
US20090191218A1 (en) * 2005-05-11 2009-07-30 Fengchun Li DNA Vaccines And Methods For The Prevention Of Transplantation Rejection
WO2009114735A1 (en) * 2008-03-12 2009-09-17 Loma Linda University Dna vaccines and methods for the prevention of transplantation rejection
EP2542698B1 (en) 2010-03-03 2015-04-22 Zymo Research Corporation Detection of dna methylation
CN105451777A (zh) * 2013-03-15 2016-03-30 洛马林达大学 自身免疫性疾病的治疗

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2058393B1 (en) * 2005-05-11 2010-07-07 Loma Linda University Compositions and methods for preventing and treating immune-mediated inflammatory disorders
WO2013044177A2 (en) * 2011-09-23 2013-03-28 Loma Linda University Bacterial strains expressing methylase genes and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YI,A.ET AL: "CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species", 《THE JOURNAL OF IMMUNOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110237270A (zh) * 2013-03-15 2019-09-17 洛马林达大学 自身免疫性疾病的治疗

Also Published As

Publication number Publication date
AU2014233428A1 (en) 2015-09-17
JP2021091742A (ja) 2021-06-17
DK2968606T3 (da) 2020-10-26
EP2968606A4 (en) 2016-10-12
JP6499155B2 (ja) 2019-04-10
AU2014233428B2 (en) 2019-09-19
CA2902565A1 (en) 2014-09-18
EP2968606A1 (en) 2016-01-20
WO2014145042A1 (en) 2014-09-18
JP2016516725A (ja) 2016-06-09
CN110237270A (zh) 2019-09-17
AU2019219835B2 (en) 2021-10-07
EP2968606B1 (en) 2020-10-07
HK1220127A1 (en) 2017-04-28
ES2825078T3 (es) 2021-05-14
JP2019077715A (ja) 2019-05-23
AU2019219835A1 (en) 2019-09-12
CA2902565C (en) 2022-11-29

Similar Documents

Publication Publication Date Title
AU2019219835B2 (en) Treatment of autoimmune diseases
AU2023210606A1 (en) Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
UA109891C2 (uk) Композиція пухлиноасоційованих пептидів для лікування ракових захворювань
US11058744B2 (en) Composition for treating prostate cancer
JP2005533000A (ja) Ｍｄａ−７に関与する免疫誘導を増強する方法
US20050020817A1 (en) Tumor antigen proteins, genes therefor, and tumor antigen peptides
US9314497B2 (en) E2F as a target of hormone refractory prostate cancer
CN111417647A (zh) 新型senolytic肽
CA2570017A1 (en) Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
US20240043866A1 (en) Treatment of autoimmune diseases
EP2751126B1 (en) Use of hdl-related molecules to treat and prevent proinflammatory conditions
HK40013739A (en) Treatment of autoimmune diseases
HK1220127B (en) Treatment of autoimmune diseases
US20080293652A1 (en) Combination of Ad-P53 and Chemotherapy for the Treatment of Tumours
KR101558222B1 (ko) 사이클로필린 ａ를 포함하는 탈모 방지 및 발모 개선을 위한 조성물
JP4280878B2 (ja) Ｍａｓｌ１遺伝子
JPWO1997046676A1 (ja) 腫瘍抗原タンパク質、その遺伝子および腫瘍抗原ペプチド
Class et al. Patent application title: USE OF A TRUNCATED EIF-5A1 POLYNUCLEOTIDE TO INDUCE APOPTOSIS IN CANCER CELLS Inventors: John E. Thompson (Waterloo, CA) Zhong Sun (Waterloo, CA) Catherine Taylor (Waterloo, CA) Catherine Taylor (Waterloo, CA) Richard Dondero (Riverdale, NJ, US) Zhenyu Cheng (Waterloo, CA)
HK1180218B (en) Methods and compositions involving mda-7
HK1180218A1 (en) Methods and compositions involving mda-7
JPWO1998022582A1 (ja) ヒト癌退縮抗原タンパク質

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160330